Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Stock Code: 300957 Stock Abbreviation: Botanee Announcement No.: 2024- 053
Yunnan Botanee Bio-Technology Group Co., Ltd.
2024 Q3 Quarterly Report
Botanee and all members of the Board of Directors guarantee that the information disclosed herein is true,
accurate and complete without false hoods, misleading statement s or major omissions.
Notices:
1. Botanee’s Board of Directors, Board of Supervisors, as well as directors, supervisors and senior management
officers guarantee that the present quarterly report is true, accurate and complete without false hoods, misleading
statements or major omissions, and undertake individual and joint legal liabilities arising therefrom.
2. Botanee’s legal representative Mr. Guo Zhenyu, CFO Mr. Wang Long, and Head of Accounting Department Mr.
Liu Zhaofeng hereby declare that the financial information herein is authentic, accurate, and complete.
3. Whether this Q3 report has been audited or not:
□ Yes No
1
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
I. Key financial data
(i) Major Accounting Data and Financial Indicators
Whether the Company needs to retrospectively adjust or restate the accounting data for the previous years
□ Yes No
Change
in the period
From the from the
Change in
beginning of the beginning of
This Reporting the
year to the end of the year to
Period Reporting
the Reporting the
Period (%)
Period end of the
Reporting
Period（%）
Operating revenue(RMB) 1,213,087,219.34 14.04% 4,017,760,019.31 17.09%
Net profit attributable to
shareholders of the listed -68,999,289.50 -153.41% 414,768,732.22 -28.39%
companies (RMB)
Net profit attributable to
shareholders of the listed
company after deducting non- -78,224,976.78 -158.23% 341,368,837.06 -32.81%
recurring Gains and Losses
(RMB)
Net cash flows from operating
6,430,018.31 -94.83%
activities (RMB)
Basic earnings per share
-0.16 -151.61% 0.99 -27.74%
(RMB/share)
Diluted earnings per share
-0.16 -153.33% 0.98 -27.94%
(RMB/share)
Decrease by
Decrease by 3.41 3.11
Weighted average ROE -1.16% 7.07%
percentage points percentage
points
Change in the End of This
End of the End of the
Reporting Year over the End of the
reporting period Previous Year
Previous Year (%)
Total assets (RMB) 7,804,443,170.41 7,506,930,342.79 3.96%
Owners' equity attributable to
shareholders of listed 5,903,907,588.93 5,860,994,371.02 0.73%
companies (RMB)
Whether the Company’s share capital has changed and affected the amount of shareholders’ equity due to secondary
public offering，placement; allotment; ESOP exercise , buybacks and other reasons from the end of the reporting
period to the disclosure date of the quarterly report.
Yes □No
Beginning of year
Current reporting
to end of reporting
period
period
Dividends for Preferred Shares That Have Been Paid ( RMB)
Interest Paid on Perpetual Bonds ( RMB)
Fully Diluted Dividends per Share Based on Latest Share -0.1629 0.9792
2
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Capital ( RMB / Share)
(ii) Item and Amount of Non-Recurring Gains and Losses
Applicable □ Not applicable
Currency: RMB
Amount from the
Amount for the
beginning to the
Item current reporting Description
end of the
period
reporting period
Gains and Losses from disposal of non-
current assets (including the offset part of 265,935.92 -1,127,052.38
provisions for impairment of assets)
Government subsidies included in the
current Gains and Losses (excluding those
Government
closely related to the normal business of the
subsidies and
Company, granted under the national 5,158,276.41 47,624,403.38
incentives included in
policies and continuously enjoyed according
“other income” item.
to certain standards with lasting impacts on
the Company’s profit and loss)
Except for the effective hedging activities
related to the Company’s ordinary activities,
Represents gain or
Gains and Losses arising from changes in
loss on change in fair
fair value of financial assets and financial -3,342,571.76 17,367,189.05
value of entrusted
liabilities held by non-financial enterprises,
cash.
and Gains and Losses arising from disposal
of financial assets and financial liabilities
Mainly investment
income generated by
Gains and losses from assets invested or
11,508,589.46 39,997,693.67 the maturity of
managed by the entrusted
entrusted cash
management
Mainly public
Other non-operating income and expenses welfare donations
-2,582,974.84 -10,518,467.93
other than the above charged to "non-
operating expenses".
Less: Effect on income tax 1,753,723.21 18,983,116.83
Effect on minority interests (after tax) 27,844.70 960,753.80
Total 9,225,687.28 73,399,895.16
Particulars about other items that meet the definition of non-recurring gain s and losses:
□ Applicable Not applicable
There is no other items that meet the definition of non-recurring gain s and losses in the Company.
Defined non-recurring gain s and losses set out in the Explanatory Announcement on Information Disclosure by
Companies Offering Securities to the Public No. 1 Non recurring Gains and Losses as recurring gain s and losses
□ Applicable Not applicable
We did not define non-recurring gains and losses set out in the Explanatory Announcement on Information
Disclosure by Companies Offering Securities to the Public No. 1 Non recurring Gains and Losses as recurring gains
and losses.
3
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
(iii) Changes in Major Accounting Data and Financial Indicators and Reasons
Applicable □ Not applicable
1. Changes in the Items of Consolidated Balance Sheet at the End of the Reporting Period and
Reasons
Currency: RMB
Balance at the End of Balance at the Proportion of
Item Increase/ Decrease
the Reporting Period Beginning of the Year increase/ decrease
Cash and cash
1,166,944,088.76 2,091,459,861.58 -924,515,772.82 -44.20%
equivalents
Financial assets held
1,975,892,720.20 1,238,356,707.34 737,536,012.86 59.56%
for trading
Notes receivable 24,502,124.46 -24,502,124.46 -100.00%
Accounts receivable 772,141,683.77 561,761,929.57 210,379,754.20 37.45%
Prepayments 110,731,725.08 69,279,116.38 41,452,608.70 59.83%
Other receivables 38,777,891.11 29,748,433.09 9,029,458.02 30.35%
Construction work in
54,133,845.53 40,220,147.41 13,913,698.12 34.59%
process
Right-of-use assets 186,949,433.90 100,712,614.93 86,236,818.97 85.63%
Intangible asset 266,963,888.68 193,108,638.64 73,855,250.04 38.25%
Deferred income tax
148,445,896.80 93,131,250.45 55,314,646.35 59.39%
assets
Short term loans 245,980,003.46 103,816,588.60 142,163,414.86 136.94%
Notes payable 143,651,602.85 67,562,710.23 76,088,892.62 112.62%
Contractual liabilities 69,312,151.22 50,053,638.68 19,258,512.54 38.48%
Employee
145,836,510.23 106,452,763.55 39,383,746.68 37.00%
remuneration payable
Other payables 105,649,402.21 449,282,195.16 -343,632,792.95 -76.48%
Non-current liabilities
72,092,918.09 42,102,294.00 29,990,624.09 71.23%
due within one year
Other current liabilities 17,059,866.66 5,455,465.77 11,604,400.89 212.71%
Long term loans 321,300,000.00 4,700,000.00 316,600,000.00 6736.17%
Lease liabilities 112,675,673.64 63,283,532.61 49,392,141.03 78.05%
Deferred income 56,067,010.53 82,862,738.40 -26,795,727.87 -32.34%
Treasury shares 234,717,526.96 109,838,205.82 124,879,321.14 113.69%
Reasons for the changes：
(1) The balance of cash at bank and on hand at the end of the reporting period stood at RMB1,166.94 million, a
4
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
decrease of RMB924.51milion or about 44.20% compared with the beginning of the year. For changes in major
cash flow s of the Company’s cash at bank and on hand during the reporting period, please refer to “3. Changes
in Items of Consolidated Balance Sheet at the End of the Reporting Period and Reasons of this report”.
(2) The total balance of financial assets held for trading at the end of the reporting period stood at RMB1,975.89
million, an increase of RMB737.54 million or about 59.56% compared with the beginning of the year, which was
mainly due to increase s in immature investment balance of cash management projects (measured at fair value)
with available funds raised and its own funds within the quota authorized by the General Meeting of Shareholders
at the end of the reporting period.
(3) There was no balance of notes receivable at the end of the period, a decrease of RMB24.50 million compared
with the beginning of the year, which was attributable to the fact that the Company had fully collected the matured
commercial acceptances from the beginning of the year to the end of the reporting period. At the end of the reporting
period, the Company had no commercial acceptances on hand.
(4) The closing balance of accounts receivable amounted to RMB772.14 million, representing an increase of
RMB210.37million, or approximately 37.45%, as compared with that at the beginning of the year, which was mainly
due to the fact that the Company's major credit customers were actively preparing for bulk purchases from the
Company for its Q4 2024 sales promotion during the reporting period, and the relevant receivables were still within
the commercial credit period as at the end of the reporting period. There was no significant change in the commercial
credit policy of the Company's major credit customers from the beginning of the year to the end of the reporting
period. The creditworthiness of the Company's credit customers was good and strong. The proportion of the
Company's accounts receivable with an age of less than one year to the balance of accounts receivable at the end of
the reporting period and at the beginning of the year was approximately 96.31% and 98.65%, respectively, with a
better ageing profile and stronger liquidity. The Company's accounts receivable are well paid back and the quality
of accounts receivable is high, and the Company believes that the possibility of bad debts arising from accounts
receivable is low. The Company has implemented a strict credit management system and a prudent bad debt
provisioning policy, and the provision for bad debts in respect of accounts receivable is adequate, with the percentage
of provision for bad debts at the end of the reporting period and the beginning of the current year amounting to
approximately 5.29% and 4.64%, respectively.
(5) The closing balance of prepayments amounted to RMB110.73 million, representing an increase of RMB41.45
million, or approximately 59.83%, as compared with the beginning of the year, which was mainly attributable to the
increase in the Company's prepayment of marketing expenses and advertising and endorsement expenses of large-
scale B2C e-commerce platforms and other marketing service providers for the fourth quarter of 2024 for the
promotion activities during the reporting period. The Company's prepayments are expected to be written off in the
next twelve months on a turnaround basis.
(6) The closing balance of other receivables amounted to RMB38.78 million, representing an increase of RMB9.03
million, or approximately 30.35%, as compared with the beginning of the year, which was mainly attributable to the
increase in deposits and guarantees paid by the Company for the purpose of carrying out its business activities from
the beginning to the end of the reporting period. The Company has implemented a strict deposit and guarantee
management system and a prudent bad debt provision policy, and the bad debt provision for other receivables was
adequate, with the bad debt provision ratio at the end of the reporting period and the beginning of the year being
5
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
approximately 18.84% and 19.97% respectively.
(7) The closing balance of construction under progress amounted to RMB54.13 million, representing an increase of
RMB13.91 million, or approximately 34.59%, compared with the beginning of the year, which was mainly
attributable to the increase in investment in the Company's sporadic engineering and construction (technological
upgrading and renovation) projects during the reporting period.
(8) The closing balance of right-of-use assets amounted to RMB186.95 million, representing an increase of
RMB86.24 million, or 85.63%, compared with the beginning of the year, which was mainly attributable to the
Company's new leasing contracts for operating sites from the beginning of the year to the end of the reporting period.
From the beginning of the year to the end of the reporting period, the Company's leased premises were mainly used
for production, research and development, warehousing and office purposes.
(9) The closing balance of intangible assets amounted to RMB 266.96 million, representing an increase of RMB
73.86 million, or approximately 38.25%, compared with the beginning of the year, which was mainly due to the
increase in the investment payment for the right to use the office software and the land use right formed by the
Company's outsourcing and internal research and development from the beginning of the year to the end of the
reporting period.
(10) The closing balance of deferred income tax assets amounted to RMB148.45 million, representing an increase
of RMB55.31 million, or 59.39%, compared with the beginning of the year, which was mainly due to the combined
effect of the increase in the balances of temporary differences in the items of "Lease liabilities" and "Deductible
losses" and the decrease in the balances of temporary differences in the item of "Government grants recognized as
deferred income" at the end of the reporting period. The increase was mainly due to the combined effect of the
increase in the balance of temporary differences between the items of "lease liabilities" and "deductible losses" and
the decrease in the balance of temporary differences in the item of "government grants recognized as deferred
income" at the end of the reporting period.
(11) The closing balance of short-term loans amounted to RMB 245.98 million, representing an increase of RMB
142.16 million, or 136.94%, from the beginning of the year to the end of the reporting period, due to the short-term
liquidity financial loans from commercial banks obtained by the Company in accordance with the dynamic capital
demand plan and actively exploring sound and diversified financing channels.
(12) The closing balance of notes payable amounted to RMB143.65 million, representing an increase of RMB76.09
million, or approximately 112.62%, compared with the beginning of the year. This was due to the fact that from the
beginning of the year to the end of the reporting period, the Company, in accordance with the dynamic capital
demand plan, actively explored sound and diversified financing channels, and the balance of the outstanding bankers'
acceptances payable issued by the Company at the end of the reporting period increased by a relatively large amount.
(13) The closing balance of contract liabilities amounted to RMB69.31 million, representing an increase of
RMB19.26 million, or approximately 38.48%, as compared with the beginning of the year, which was mainly
attributable to the combined effect of the increase in the balance of the Company's advance receipts and provision
for sales rebates and unredeemed credit reserves at the end of the reporting period.
6
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
(14) The ending balance of compensation payable to employees amounted to RMB145.84 million, representing an
increase of RMB39.38 million, or approximately 37.00%, as compared to the beginning of the current year, which
was mainly attributable to the increase in the amount of the Company's FY201024 year-end bonus (nine months)
and the balance of the performance bonus for the third quarter of FY2024, which were accrued in accordance with
the accounting period at the end of the reporting period.
(15) The closing balance of other payables amounted to RMB105.65 million, a decrease of RMB343.63 million from
the beginning of the year, a decrease of approximately 76.48%, mainly due to the fact that from the beginning of the
year to the end of the reporting period, the Company paid the various due marketing expenses incurred in the fourth
quarter of the previous year in respect of the large-scale B2C e-commerce platforms and other marketing service
providers, and the balance of other payables decreased accordingly.
(16) The closing balance of other current liabilities amounted to RMB17.06 million, representing an increase of
RMB11.60 million, or approximately 212.71%, compared with the beginning of the year, which was mainly
attributable to the increase in the balance of the provision for expected return of goods (payable for return of goods)
made by the Company during the reporting period.
(17) The closing balance of long-term loans amounted to RMB321.30 million, representing a significant increase
from the beginning of the year, which was attributable to the long-term project loans from commercial banks
obtained by the Company from the beginning of the year to the end of the reporting period.
(18) Non-current liabilities due within one year and lease liabilities totaled RMB184.77 million at the end of the
period, representing an increase of RMB79.38 million, or approximately 75.33%, compared with the beginning of
the year, which was mainly attributable to the increase in the amount of lease payments for operating sites for which
the Company had not yet met the payment terms at the end of the reporting period. From the beginning of the year
to the end of the reporting period, the Company's leased premises were mainly used for production, research and
development, warehousing and office purposes. From the beginning to the end of the reporting period, the closing
balance of the Company's right-of-use assets basically matched the trend and magnitude of the increase in the closing
balance of non-current liabilities and lease liabilities due within one year.
(19) The ending balance of deferred income was RMB56.07 million, a decrease of RMB26.80 million or
approximately 32.34%, compared with the beginning of the year, which was mainly due to the higher amortization
of government grants for special research and development funds from the beginning of the year to the end of the
reporting period in accordance with the progress of the implementation of the scientific and technological projects
of the Specialty Plants Laboratory of Yunnan Province.
(20) The closing balance of treasury shares was RMB234.72 million, representing an increase of RMB124.88 million,
or approximately 113.69%, as compared with the beginning of the year, which was attributable to the repurchase of
shares of the Company's ordinary shares through centralized bidding and trading with its own funds pursuant to the
resolution of the Board of Directors during the reporting period.
7
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
2. Changes in the Items of Consolidated Income Statement from the Beginning of the Year to
the End of the Reporting Period and Reasons
Currency: RMB
Amount Incurred in Proportion on
Item Current Amount the Same Period of Change Increase/
the Previous Year Decrease
Operating revenue 4,017,760,019.31 3,431,483,300.01 586,276,719.30 17.09%
Operating costs 1,055,538,266.19 809,234,537.42 246,303,728.77 30.44%
Marketing expenses 2,009,988,137.89 1,604,575,219.78 405,412,918.11 25.27%
Administration expenses 339,559,239.61 244,208,517.61 95,350,722.00 39.04%
Financial cost -2,693,413.82 -16,439,866.87 13,746,453.05 83.62%
Gain (loss recognized as "-") on
17,367,189.05 -24,026,395.24 41,393,584.29 172.28%
change in fair value
Non-operating expenses 12,385,601.16 8,153,423.12 4,232,178.04 51.91%
Net profit attributable to
414,768,732.22 579,190,052.04 -164,421,319.82 -28.39%
shareholders of the parent company
Analysis of reasons for changes:
(1) The operating revenue of the Company from the beginning of the year to the end of the reporting period amounted
to RMB4,017.76 million, representing an increase of RMB586.28 million, or approximately 17.09%, over the same
period of the previous year, which was mainly attributable to the combined effect of the increase in the scale of sales
of the Company from the beginning of the year to the end of the reporting period as compared with that of the same
period of the previous year, as well as the incorporation of Yue Jiang (Guangzhou) Investment Co. (hereinafter
referred to as "ME Investment") was included in the scope of consolidation of the Company from October 31, 2023
onwards.
(2) The operating costs of the Company from the beginning of the year to the end of the reporting period amounted
to RMB1,055.54 million, representing an increase of RMB246.30 million, or approximately 30.44%, compared with
the same period of the previous year, which was mainly attributable to the increase in operating costs in the same
direction with the growth of the Company's sales scale and sales revenue. From the beginning of the year to the end
of the reporting period, the production cost of the Company's main products basically remained stable.
(3) The gross profit margin of the Company from the beginning of the year to the end of the reporting period was
approximately 73.73%, representing a decrease of approximately 2.69 percentage points as compared with the same
period of the previous year. Among them, Yuejiang Investment's "Za" and "PURE&MILD" brands realized operating
income of RMB381.00 million from the beginning of the year to the end of the reporting period, with a gross profit
margin of approximately 58.37%; according to the scope of statistics for the same period last year, the company's
"Winona (Winona)" brand realized gross profit margin of approximately 73.73% compared with the same period last
year. According to the statistical scope of the same period last year, the company "Winona (Winona)" and other
major brands from the beginning to the end of the reporting period to achieve a total operating income of
RMB3,636.76 million , an increase of about 5.98% compared with the same period of the previous year, gross profit
8
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
margin of sales of about 75.34%. The increase in operating costs from the beginning to the end of the reporting
period was slightly higher than the increase in operating income, mainly due to the combined effect of the company's
promotional policies and the dynamic response of the sales structure of its products (brands) in accordance with
market demand from the beginning to the end of the reporting period.
(4) The Company's selling expenses from the beginning of the year to the end of the reporting period amounted to
RMB2,009.99 million, representing an increase of RMB405.41 million, or approximately 25.27%, over the same
period of the previous year, which was mainly attributable to the growth in the Company's sales scale and sales
revenue, and the Company's continued increase in the investment in the promotion and publicity expenses of its
brand image, personnel expenses and storage expenses. From the beginning to the end of the reporting period, the
growth of the Company's selling expenses was higher than the growth of sales scale, which was mainly due to the
combined effect of the Company's initiative to increase its promotional inputs such as grass-raising and traffic
attraction in Jitterbug channels, and the increase in advertising and marketing inputs such as brand endorsement and
co-branding activities in order to drive the Company's and the brand's sound volume to increase and to warm up for
the omni-channel promotion activities in the fourth quarter of 2024 during the reporting period.
(5) The administrative expenses of the Company from the beginning of the year to the end of the reporting period
amounted to RMB339.56 million, representing an increase of RMB95.35 million, or approximately 39.04%, over
the same period of the previous year. The increase in the Company's administrative expenses from the beginning to
the end of the reporting period was higher than the increase in sales scale, which was mainly due to the accrual of
equity incentive expenses for the employee shareholding plan during the reporting period. The management expenses
such as administrative personnel expenses, depreciation and amortization costs of long-term assets for management
purposes and other administrative expenses from the beginning to the end of the reporting period were basically
matched with the growth in sales scale of the Company.
(6) Finance cost (net income) of the Company from the beginning to the end of the reporting period amounted to
RMB2.69 million, a decrease of RMB13.75 million, or 83.62%, compared with the same period of the previous year,
which was mainly due to the combined effect of the increase in interest expenses from the beginning to the end of
the reporting period as compared with that of the same period of the previous year, as well as the decrease in interest
income from demand deposits as compared with that of the same period of the previous year.
(7) The Company's net gain from changes in fair value from the beginning of the year to the end of the reporting
period amounted to RMB17.37 million, an increase of RMB41.39 million in net gain compared with the same period
of the previous year, and a significant increase in net gain year-on-year, which was mainly attributable to the increase
in the fair value of a number of entrusted wealth management (measured at fair value) items held by the Company
in its cash management investments from the beginning of the year to the end of the reporting period.
(8) The non-operating expenses of the Company from the beginning of the year to the end of the reporting period
amounted to RMB12.39 million, representing an increase of RMB4.23 million, or 51.91%, compared with the same
period of the previous year, which was mainly attributable to the increase in the Company's expenditure on external
public welfare donations from the beginning of the year to the end of the reporting period.
(9) From the beginning of the year to the end of the reporting period of the company's net profit attributable to
shareholders of the parent company of 414.77 million RMB, compared with the same period of the previous year
9
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
decreased by RMB164.42 million, a decrease of about 28.39%, mainly due to the company's operating income
continued to grow, the gross profit margin of the sales of the product (brand) sales structure due to the causes of a
slight decline in sales as well as the various types of operating expenses phased (or project) rise in the combined
impact of the company.
3. Changes in the Items of Consolidated Statement of Cash Flow from the Beginning of the
Year to the End of the Reporting Period and Reasons
Currency: RMB
Amount Incurred in the Proportion on
Item Current Amount Same Period of the Increase/ decrease Increase/
Previous Year Decrease
Cash inflow from business
4,202,318,121.88 3,724,241,068.30 478,077,053.58 12.84%
operations
Cash outflow from business
4,195,888,103.57 3,599,775,539.27 596,112,564.30 16.56%
operations
Cash inflow from
3,059,332,916.32 3,890,122,959.93 -830,790,043.61 -21.36%
investment activities
Cash outflow from
4,081,959,077.20 4,430,128,738.30 -348,169,661.10 -7.86%
investment activities
Cash inflow from
669,280,043.91 7,500,000.00 661,780,043.91 8,823.73%
financing activities
Cash outflow from
662,755,180.80 399,526,671.95 263,228,508.85 65.89%
financing activities
Analysis of reasons for change:
(1) Cash inflow from operating activities from the beginning to the end of the reporting period amounted to
RMB4,202.32 million, an increase of RMB478.08 million or 12.84% over the same period of the previous year,
which was mainly due to the increase in cash inflow from the growth in sales scale and sales revenue of the Company.
From the beginning to the end of the reporting period, the growth of the item "cash received from sales of goods and
services" in the company's operating activities was basically matched with the growth of sales scale. As the
government grants and special payables received by the Company from the beginning to the end of the reporting
period decreased more than that of the same period last year, "cash received from other operating activities"
decreased by RMB97.20 million year-on-year, or about 65.16%.
(2) From the beginning to the end of the reporting period, the company's cash outflow from operating activities
amounted to RMB 4,195.89 million, an increase of RMB 596.11 million over the same period of the previous year,
an increase of approximately 16.56%, which was mainly due to the increase in the company's other operating
expenditures such as brand image promotion and publicity costs, personnel costs and storage costs inputs with the
increase in sales scale. From the beginning of the year to the end of the reporting period of the company's cash
outflow from operating activities growth and sales scale growth basically match.
10
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
(3) The Company's cash inflow from investing activities from the beginning to the end of the reporting period
amounted to RMB3,059.33 million, a decrease of RMB830.79 million, or approximately 21.36%, compared with
the same period of the previous year, which was mainly due to the fact that the Company's major cash management
entrusted wealth management investment projects had not yet matured at the end of the reporting period.
(4) Cash outflow from investing activities of the Company from the beginning of the year to the end of the reporting
period amounted to RMB 4,081.96 million, a decrease of RMB 348.17 million, or 7.86%, compared with that of the
same period of the previous year, mainly due to the fact that the Company's major cash management entrusted wealth
management investment projects had not yet expired at the end of the reporting period, and the Company's remaining
amount of cash management investment that could be made with idle fund-raising funds and idle own funds
authorized by the general meeting of shareholders was reduced. The decrease was mainly due to the decrease in the
amount of cash management entrusted financial investment paid by the Company from the beginning to the end of
the reporting period.
(5) The cash inflow from financing activities of the Company from the beginning to the end of the reporting period
amounted to RMB669.28 million million, representing a substantial increase compared with the same period of the
previous year, which was mainly attributable to the short-term liquidity financial loans and long-term project loans
from commercial banks obtained by the Company in accordance with its dynamic capital demand plan and actively
exploring sound and diversified financing channels during the reporting period.
(6) Cash outflow from financing activities of the Company from the beginning to the end of the reporting period
amounted to RMB662.76 million, representing an increase of RMB263.23 million, or 65.89%, compared with the
same period of last year. This was mainly due to the combined effect of the repayment of maturing commercial
bank loans by the Company from the beginning of the year to the end of the reporting period, the decrease in the
distribution of annual cash dividends to all shareholders as compared with the same period of the previous year,
and the increase in the amount of the Company's own funds utilized to repurchase the Company's ordinary shares
by way of centralized competitive bidding in accordance with the resolution of the Board of Directors.
II. Shareholders information
(i) Total Number of Ordinary Shareholders and the Number of Preferred Shareholders
Whose Voting Rights Have Been Restored and Shareholding of Top 10 Shareholders
Unit: shares
Total number of
ordinary Total number of preferred shareholders
shareholders at 36,570 with voting rights restored at the end of
the end of the the reporting period (if any)
reporting period
Shareholdings of the top 10 shareholders (excluding shares lent through conversion)
Number of Pledged, marked or
shares frozen shares
Nature of Shareholding Number of
Name subject
shareholder proportion shares held Status of
to trading Quantity
shares
restriction
11
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Kunming Nuona Domestic non-
Technology state-owned 46.08% 195,212,611
Co., Ltd. corporation
Tianjin Sequoia
Juye Equity
Domestic non-
Investment
state-owned 14.58% 61,763,257
Partnership
corporation
(Limited
partnership)
Xiamen Zhenli Domestic non-
Consulting state-owned 6.54% 27,685,934
Co., Ltd. corporation
Hong Kong
Securities
Overseas Legal
Clearing 3.01% 12,729,726
Entity
Company
Limited
Yunnan
Haqisheng
Domestic non-
Enterprise
state-owned 2.60% 10,993,678
Management
corporation
Co.,
Ltd.
Kuwait
Overseas legal
Investment 1.25% 5,285,437
persons
Authority
Xiamen
Chonglou
Yunshui Domestic non-
Investment state-owned 1.09% 4,614,770
Partnership corporation
(Limited
Partnership)
Industrial and
Commercial
Bank of China
Limited Efund Miscellaneous
0.88% 3,706,881
GEM Exchange
traded Open
Index Securities
Investment Fund
National Social
Security Fund Miscellaneous 0.66% 2,816,813
102 Portfolio
Industrial and
Commercial
Bank of China
Limited - Huatai Miscellaneous 0.62% 2,621,584
Berridge CSI 300
Traded Open-
End Index Fund
Shareholdings of top 10 shareholders with unlimited sales conditions (excluding shares lent through conversion
and shares locked up by executives)
Number of shares not subject to trading Type and number of
shares
Shareholder restriction as at the end of reporting
Type of
period quantities
shares
12
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Kunming Nuona Technology Co., RMB
195,212,6
195,212,611 common
Ltd. 11
shares
Tianjin Sequoia Juye Equity RMB
61,763,25
Investment Partnership 61,763,257 common
7
(Limited Partnership) shares
RMB
27,685,93
Xiamen Zhenli Consulting Co., Ltd. 27,685,934 common
4
shares
Hong Kong Securities Clearing RMB
12,729,72
12,729,726 common
Company Limited 6
shares
RMB
Yunnan Haqisheng Enterprise 10,993,67
10,993,678 common
Management Co., Ltd. 8
shares
RMB
Government of Kuwait Investment
5,285,437 common 5,285,437
Authority
shares
Xiamen Chonglou Yunshui RMB
Investment Partnership (Limited 4,614,770 common 4,614,770
Partnership) shares
Industrial and Commercial Bank of
China Limited RMB
Efund GEM Exchange traded Open 3,706,881 common 3,706,881
Index Securities shares
Investment Fund
National Social Security Fund 102 RMB
2,816,813 common 2,816,813
Portfolio
shares
Industrial and Commercial Bank of RMB
China Limited - Huatai Berridge CSI 2,621,584 common 2,621,584
300 Traded Open-End Index Fund shares
Kunming Nuona Technology Co., Ltd. and Yunnan Haqisheng
Description on the related relationship Enterprise Management Co., Ltd. are both controlled by Guo Zhenyu
or concerted and Kevin Guo (father and the actual controllers of Botanee . Except
action among the above shareholders this, we do not know whether other shareholders have an association
or a concerted action relationship.
Description of top 10 shareholders
participating in Not applicable.
securities margin trading (if any)
Shareholders holding more than 5% of shares, top 10 shareholders and top 10 shareholders with unlimited shares in
circulation participating in the lending of shares in the transfer and financing business
Applicable □ Not applicable
Unit: shares
Shareholders holding more than 5% of shares, top 10 shareholders and top 10 shareholders with unlimited shares
in circulation participating in the lending of shares in the transfer and financing business
Shares lent on
Shares lent on the the transfer
Name of General and credit General and credit
opening transfer facility at the
shareholder account holdings at the account holdings at
facility and not yet end of the
(full name) beginning of the period the end of the period
returned period and not
yet repatriated
13
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Percen
Percent Percent
Percentag tage
age of age of
Total e of total of Total
Total number total Total number total
number share total number
share share
capital share
capital capital
capital
Industrial and
Commercial
Bank of
China
Limited - 1,507,481 0.36% 466,500 0.11% 3,706,881 0.88%
Efounda
GEM Trading
Open-End
Index Fund
Industrial and
Commercial
Bank of
China
Limited -
993,000 0.23% 205,000 0.05% 2,621,584 0.62%
Huatai
Berridge CSI
300 Traded
Open-End
Index Fund
Top 10 shareholders and top 10 shareholders with unlimited shares outstanding change from the previous period due
to lending/return of convertible bonds
□ Applicable Not applicable
(ii) Total number of preferred shareholders and shareholdings of the top 10 preferred
shareholders of the Company
□ Applicable Not applicable
(iii) Changes in restricted shares
Applicable □ Not applicable
Unit: shares
Increase in
Number of Number of the number of Number of
restricted shares shares subject restricted Reasons for
Name of Date of
shares at the released from to selling shares at the trading
Shareholder unlocking
beginning of lock-up during restrictions end of the restriction
the period the period during the period
period
Kunming
Nuona Pre-IPO March 25,
195,212,611 195,212,611
Technology shares 2024
Co., Ltd.
Yunnan
Pre-IPO March 25,
Haqisheng 10,993,678 10,993,678
shares 2024
Enterprise
14
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Management
Co., Ltd.
Total 206,206,289 206,206,289
iii. Other important matters
Applicable□Not applicable
For details, please refer to the following important announcement of significant matters disclosed on the China
Securities Regulatory Information Net (http://www.cninfo.com.cn).
Announcement
Other important matters
disclosure date
Botanee: Board Resolution Announcement August 28, 2024
Botanee: Announcement on the Election of an Independent Director August 28, 2024
Botanee: Resolution Announcement of the First Extraordinary General Meeting of Yunnan Botanee
September 19, 2024
Biotechnology Group Co., Ltd. in 2024
Botanee: Announcement on the Completion of Non-Transactional Transfer of the 2024 Employee Stock
September 26, 2024
Ownership Plan by Yunnan Botanee Biotechnology Group Co., Ltd.
Botanee: Announcement on the Completion of Industrial and Commercial Change Registration and the
September 30, 2024
Issuance of a New Business License
IV. Quarterly financial statements
(i) Financial statements
1. Consolidated balance sheet
Prepared by: Yunnan Botanee Bio-Technology Group Co., Ltd.
September 30, 2024
Currency: RMB
Item Ending balance Opening balance
Current assets:
Cash and cash equivalents 1,166,944,088.76 2,091,459,861.58
Settlement reserves
Loans to banks and other financial institutions
Financial assets held for trading 1,975,892,720.20 1,238,356,707.34
Derivative financial asset
Notes receivable 24,502,124.46
Accounts receivable 772,141,683.77 561,761,929.57
Receivables financing 158,885,994.32 156,659,263.78
Prepayments 110,731,725.08 69,279,116.38
Premiums receivable
15
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Reinsurance premium receivable
Reserve for reinsurance contracts receivable
Other receivables 38,777,891.11 29,748,433.09
Including: interest receivable
Dividends receivable
Financial assets purchased under agreement store sell
Inventories 907,260,378.94 904,413,283.67
Including: d ata resources
Contract assets
Held for sale assets
Non-current assets due within one year
Other current assets 434,864,396.83 446,396,252.76
Total current assets 5,565,498,879.01 5,522,576,972.63
Non-current assets:
Disbursement of loans and advances to customers
Debt investment
Other debt investment
Long-term receivables
Long-term equity investment 242,682,861.29 212,015,151.15
Investment in other equity instruments
Other non-current financial assets 91,257,166.53 86,449,823.00
investment property 11,283,316.10 9,021,481.56
fixed assets 668,651,442.61 667,204,436.83
Projects under construction 54,133,845.53 40,220,147.41
Productive biological assets
oil and gas assets
Right of use assets 186,949,433.90 100,712,614.93
intangible asset 266,963,888.68 193,108,638.64
Including: data resources
development expenditure
Including: data resources
Goodwill 413,740,760.61 413,740,760.61
Long-term amortized expenses 97,510,734.07 93,317,644.84
Deferred tax assets 148,445,896.80 93,131,250.45
Other non-current assets 57,324,945.28 75,431,420.74
Total non-current assets 2,238,944,291.40 1,984,353,370.16
Total assets 7,804,443,170.41 7,506,930,342.79
Current liabilities:
short term loan 245,980,003.46 103,816,588.60
Borrowing from the Central Bank
16
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Placements from banks and other financial institutions
Financial liabilities held for trading
Derivative financial liabilities
notes payable 143,651,602.85 67,562,710.23
accounts payable 295,389,468.01 334,370,604.40
Advances from customers
Contractual liabilities 69,312,151.22 50,053,638.68
Financial assets sold under agreements to repurchase
Customer bank deposits and due to banks and other
financial institutions
Customer brokerage deposits
Securities underwriting broker age deposits
Employee remuneration payable 145,836,510.23 106,452,763.55
Taxes payable 114,885,251.36 132,117,765.46
Other accounts payable 105,649,402.21 449,282,195.16
Including: Interest payable
dividend payable 4,305.04
Handling charges and commission payable
Reinsurance premium payable
Held for sale liabilities
Non-current liabilities due within one year 72,092,918.09 42,102,294.00
Other current liabilities 17,059,866.66 5,455,465.77
Total current liabilities 1,209,857,174.09 1,291,214,025.85
Non-current liabilities:
Insurance contract reserves
Long term borrowings 857,142.85 321,300,000.00 4,700,000.00
Bonds payable
Including: Preferred shares
perpetual bond
Lease liabilities 112,675,673.64 63,283,532.61
Long term payables 8,600,000.00 8,600,000.00
Long term employee benefits payable
Estimated liabilities
Deferred income 56,067,010.53 82,862,738.40
Deferred income tax liabilities 48,997,344.70 40,452,457.50
Other non-current liabilities
Total non-current liabilities 547,640,028.87 199,898,728.51
Total liabilities 1,757,497,202.96 1,491,112,754.36
Owners equity:
Share capital 423,600,000.00 423,600,000.00
Other equity instruments
17
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Including: Preferred shares
perpetual bond
Capital reserves 2,849,688,505.04 2,846,004,685.04
Less: Treasury stock 234,717,526.96 109,838,205.82
Other comprehensive income 1,754,310.38 47,153.49
Special reserves
Surplus reserve 211,081,299.10 211,081,299.10
General risk provision
Undistributed profit 2,652,501,001.37 2,490,099,439.21
Total owner equity attributable to the parent company 5,903,907,588.93 5,860,994,371.02
Minority interest 143,038,378.52 154,823,217.41
Total owners' equity 6,046,945,967.45 6,015,817,588.43
Total liabilities and owners' equity 7,804,443,170.41 7,506,930,342.79
Legal representative: GUO ZHENYU (Guo Zhenyu) Responsible for accounting work: Wang Long Head of
accounting organization: Liu Zhaofeng
2. Consolidated statement of income from the beginning of the year to the end of the reporting
period
Currency: RMB
Amount incurred
Amount incurred in
Item in
current period
previous period
I. Gross operating income 4,017,760,019.31 3,431,483,300.01
Including: Operating income 4,017,760,019.31 3,431,483,300.01
Interest income
Premiums earned
Fee and commission income
II. Total operating costs 3,633,039,744.40 2,858,745,120.50
Including: Operating costs 1,055,538,266.19 809,234,537.42
interest expense
Handling fee and commission expenses
surrender charge
Net payments for insurance claims
Net provision for insurance contract reserves
Policy dividend expenses
Reinsurance expenses
Taxes and surcharges 30,900,651.60 35,221,136.14
Selling expenses 2,009,988,137.89 1,604,575,219.78
Management expenses 339,559,239.61 244,208,517.61
R&D expenses 199,746,862.93 181,945,576.42
financial expenses -2,693,413.82 -16,439,866.87
18
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Including: Interest expense 12,018,475.64 3,783,482.38
Interest income -16,278,220.04 -21,048,656.14
Add: Other gains 53,557,665.37 72,269,211.02
Investment income (losses are recognized with a "-" sign) 46,065,428.13 43,954,011.19
Including: income from investment in associates and
6,067,734.46 2,575,671.82
joint ventures
Revenue from de-recognition of financial
assets 11,037,059.92 22,253,486.49
at amortized cost
Exchange earnings (losses are marked with "-")
Net exposure hedging income (losses are marked with "-")
Profit arising from changes in fair value (losses are marked
17,367,189.05 -24,026,395.24
with "-")
Credit impairment losses (losses are marked with "-") -16,776,630.99 -18,828,711.66
Impairment losses on assets (losses are marked with "-") -10,032,226.21 -10,373,286.18
Incomes of assets disposal (losses are marked with "-") -1,127,052.38 690,013.19
III. Operating profit (loss is shown with a "-" sign) 473,774,647.88 636,423,021.83
Add: Non-operating income 1,867,133.23 597,381.99
Less: Non-operating expenses 12,385,601.16 8,153,423.12
IV. Total profit (losses are marked with “-”) 463,256,179.95 628,866,980.70
Less: Income tax expense 58,740,038.04 63,784,534.19
V. Net profit (net loss is marked with “-”) 404,516,141.91 565,082,446.51
(i) Classified by going concern
1. Net profit from continuing operations (net losses are marked
404,516,141.91 565,082,446.51
with “-”)
2. Net profit from discontinued operations (net losses are
marked with “-”)
(ii) Classified by attribution of ownership
1. Net profit attributable to shareholders of the parent
414,768,732.22 579,190,052.04
company (losses are marked with “-”)
2. Minority shareholders' gains and losses (net losses are
-10,252,590.31 -14,107,605.53
shown with a "-" sign)
VI. Net of tax of other comprehensive income 1,707,156.89
Other net after tax comprehensive income attributable to the
1,707,156.89
owners of the parent company
(i) Other comprehensive income not reclassifiable to profit or
loss
1. Changes arising from re measurement of the defined
benefit plan
2. Other comprehensive incomes that cannot be reclassified
into profit or loss under the equity method
3. Changes in fair value of other equity instrument
investments
4. 4. Changes in fair value of the Company’s credit risk
5. Other
(ii) (II) Other comprehensive income to be reclassified into
1,707,156.89
profit or loss
19
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
1. Other comprehensive income that can be reclassified
into profit or loss under the equity method
2. Changes in fair value of other creditor's rights
investments
3. Amount of financial assets reclassified into
other comprehensive incomes
4. Provision for impairment of credit in other debt
investments
5. Reserves for cash flow hedge
6. Translation difference arising from foreign currency
1,707,156.89
financial statements
7. Other
Other net after tax comprehensive income attributable to
minority shareholders
VII. Total comprehensive income 406,223,298.80 565,082,446.51
(i) Total comprehensive income attributable to owners of the
416,475,889.11 579,190,052.04
parent company
(ii) Total comprehensive income attributable to minority
-10,252,590.31 -14,107,605.53
shareholders
VIII. Earnings per share:
(i) Basic earnings per share 0.99 1.37
(ii) Diluted earnings per share 0.98 1.36
If a business combination under the same control occurred during the current period, the net profit realized by the
party to be combined before the combination was: RMB0.00, and the net profit realized by the party to be combined
during the previous period was: RMB0.00.
Legal representative: GUO ZHENYU (Guo Zhenyu) Responsible for accounting work: Wang Long Head of
accounting organization: Liu Zhaofeng
3. Consolidated statement of cash flows from the beginning of the year to the end of the
reporting period
Currency: RMB
Current period's Prior period's
Item
incidence incidence
i. Cash flows from operating activities:
Cash received from sales of goods and services 4,150,344,725.28 3,573,436,910.68
Net increase in customer deposits and interbank deposits
Net increase in borrowing from central banks
Net increase in remittances to other financial institutions
Cash received from premiums for original insurance
contracts
Net cash received from reinsurance operations
Net increase in policyholder deposits and investments
Cash received for interest, fees and commissions
Net increase in inward remittances
Net increase in funding of repurchase operations
Net cash received from agency trading of securities
Tax refunds received 1,630,856.89
20
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Other cash received in connection with operating activities 51,973,396.60 149,173,300.73
Subtotal cash inflow from operating activities 4,202,318,121.88 3,724,241,068.30
Cash paid for goods and services 1,005,373,762.95 1,053,969,466.72
Net increase in loans and advances to customers
Net increase in deposits with central banks and interbanks
Cash payments for original insurance contract claims
Net increase in funds disbursed
Cash paid for interest, fees and commissions
Cash to pay policy dividends
Cash paid to and for employees 604,362,717.49 509,119,848.43
Taxes paid 326,027,800.23 359,500,880.23
Payments of other cash related to operating activities 2,260,123,822.90 1,677,185,343.89
Subtotal cash outflows from operating activities 4,195,888,103.57 3,599,775,539.27
Net cash flows from operating activities 6,430,018.31 124,465,529.03
II. Cash flows from investing activities:
Cash received from recovery of investments 3,016,000,000.00 3,837,117,111.10
Cash received from investment income 42,100,345.36 49,977,252.83
Net cash recovered from disposal of fixed assets, intangible
1,232,570.96 3,028,596.00
assets and other long-term assets
Net cash received from disposal of subsidiaries and other
operating units
Other cash received related to investing activities
Subtotal cash inflows from investing activities 3,059,332,916.32 3,890,122,959.93
Cash paid for acquisition of fixed assets, intangible assets
256,370,321.69 155,177,265.42
and other long-term assets
Cash paid for investments 3,825,588,755.51 4,270,949,388.23
Net increase in pledged loans
Net cash paid for acquisition of subsidiaries and other
4,002,084.65
operating units
Payments of other cash related to investing activities
Subtotal cash outflows from investing activities 4,081,959,077.20 4,430,128,738.30
Net cash flows from investing activities -1,022,626,160.88 -540,005,778.37
III. Cash flows from financing activities:
Cash received from absorption of investments 40.45 7,500,000.00
Including: Cash received by subsidiaries from minority
40.45 7,500,000.00
investments
Cash received from acquisition of loans 669,280,003.46
Other cash received related to financing activities
Subtotal cash inflow from financing activities 669,280,043.91 7,500,000.00
Cash paid for debt service 210,500,000.00
Cash paid for distribution of dividends, profits or interest
260,571,328.55 340,681,873.24
payments
Including: Dividends and profits paid by subsidiaries to
1,524,590.73 1,801,873.24
minority shareholders
21
Quarterly Report 2024 Q3 of Yunnan Botanee Bio-Technology Group Co., Ltd.
Payments of other cash related to financing activities 191,683,852.25 58,844,798.71
Subtotal cash outflows from financing activities 662,755,180.80 399,526,671.95
Net cash flows from financing activities 6,524,863.11 -392,026,671.95
IV. Impact of exchange rate changes on cash and cash
1,267,109.90 5,023.00
equivalents
V. Net increase in cash and cash equivalents -1,008,404,169.56 -807,561,898.29
Add: Cash and cash equivalents balance at beginning of
2,073,592,890.89 2,440,692,701.42
period
VI. Cash and cash equivalents balance at end of period 1,065,188,721.33 1,633,130,803.13
Legal representative: GUO ZHENYU (Guo Zhenyu) Responsible for accounting work: Wang Long Head of
accounting organization: Liu Zhaofeng
(ii) Adjustments to financial statements at the beginning of the year of first implementation of
new accounting standards for the first time starting from 2024
□ Applicable Not applicable
(iii) Audit reports
Whether the third quarterly report was audited
□ Yes No
The company's third quarter report is unaudited.
Board of Directors of Yunnan Botanee Bio Technology Group Co., Ltd.
October 23, 2024
22
